Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas

Summary

The purpose of this study is to preliminarily evaluate the safety and efficacy of cabergoline combined hydroxychloroquine/chloroquine(HCQ/CQ) therapy for cabergoline-Resistant Prolactinomas

Conditions

• Resistance, Disease
• Prolactinoma

Interventions

DRUG

HCQ/CQ and CAB combined treatment

Subjects are treated with hydroxychloroquine sulfate tablets 5mg/kg Bid and cabergoline tablets 2mg/week for 3 months.After therapy of 3 months the medication will be stopped if does not reduce prl level more than 20% or failure to decrease prolactinoma size.

Sponsors & Collaborators

• Xinqiao Hospital of Chongqing

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Beijing Tiantan Hospital

  collaborator OTHER

• First Affiliated Hospital of Wenzhou Medical University

  collaborator OTHER

• First Affiliated Hospital of Fujian Medical University

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Huashan Hospital

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• Zhebao Wu

  lead OTHER

Principal Investigators

• Zhebao Wu, Medical · Ruijin Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-10-25

Primary Completion

2020-12-30

Completion

2020-12-30

Countries

• China

Study Locations